AVTR Stock Analysis: Avantor | NYSE
Medical Instruments & Supplies | NYSE, USA | Market Cap: 11.303m USD | 12M Return: 33.5% | US05352A1007 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 153M
EPS Trend: -88.3%
Qual. Beats: 2
Rev. Trend: -91.8%
Qual. Beats: 4
Warnings
Tailwinds
Seasonality 7.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Avantor, Inc. (NYSE: AVTR) is a U.S.-based supplier of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries, with operations across the Americas, Europe, Asia, the Middle East, and Africa. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania, and went public on the NYSE in May 2019.
The business operates across three core offerings: materials and consumables (including purity chemicals, reagents, lab supplies, single-use assemblies, chromatography resins, and clinical trial kits); equipment and instrumentation (such as filtration systems, incubators, analytical instruments, ultra-low-temperature freezers, and peristaltic pumps); and services and specialty procurement, which includes onsite lab and production support, sourcing, and biopharmaceutical material scale-up. It also provides scientific research support services like DNA extraction, bioreactor servicing, compound management, and cleanroom maintenance.
Avantor sits within the Life Sciences Tools & Services sub-industry of the Health Care sector, supplying inputs that are largely non-discretionary for its customers research and production workflows, which supports a recurring, project-based revenue profile tied to drug development, diagnostics, and broader lab activity.
- Biopharma revenue growth accelerates as biotech funding rebounds
- Operating margins under pressure from inflation and acquisition costs
- Leverage reduction remains key focus after recent acquisitions
| Net Income: 337.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.71 > 1.0 |
| NWC/Revenue: 18.44% < 20% (prev 11.27%; Δ 7.17% < -1%) |
| CFO/TA 0.05 > 3% & CFO 584.7m > Net Income 337.2m |
| Net Debt (3.22b) to EBITDA (909.3m): 3.54 < 3 |
| Current Ratio: 1.89 > 1.5 & < 3 |
| Outstanding Shares: last quarter (680.9m) vs 12m ago -0.12% < -2% |
| Gross Margin: 31.59% > 18% (prev 33.13%; Δ -1.54% > 0.5%) |
| Asset Turnover: 56.94% > 50% (prev 56.31%; Δ 0.63% > 0%) |
| Interest Coverage Ratio: 2.81 > 6 (EBIT TTM 490.1m / Interest Expense TTM 174.6m) |
| A: 0.11 (Total Current Assets 2.59b - Total Current Liabilities 1.37b) / Total Assets 11.6b |
| B: 0.17 (Retained Earnings 1.96b / Total Assets 11.6b) |
| C: 0.04 (EBIT TTM 490.1m / Avg Total Assets 11.7b) |
| D: 1.01 (Book Value of Equity 5.84b / Total Liabilities 5.79b) |
| Altman-Z'' = 2.58 = A |
| DSRI: 1.03 (Receivables 1.12b/1.08b, Revenue 6.64b/6.58b) |
| GMI: 1.05 (GM 33.13% / 31.59%) |
| AQI: 0.96 (AQ_t 0.71 / AQ_t-1 0.74) |
| SGI: 1.01 (Revenue 6.64b / 6.58b) |
| TATA: -0.02 (NI 337.2m - CFO 584.7m) / TA 11.6b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of November 05, 2026, the stock is trading at USD 15.59 with a total of 8,756,775 shares traded. Over the past week, the price has changed by -8.99%, over one month by -1.39%, over three months by +14.05% and over the past year by +33.48%.
Current recommended Stop Loss: 14.90 (which is 4.4% or 1.3 ATR below the current price).
Avantor has received a consensus analysts rating of 3.20. Therefore, it is recommended to hold AVTR.
- StrongBuy: 2
- Buy: 0
- Hold: 12
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 17.4 | 11.3% |
P/E Trailing = 33.36
P/E Forward = 19.084
P/S = 1.7049
P/B = 1.9379
Revenue TTM = 6.64b USD
EBIT TTM = 490.1m USD
EBITDA TTM = 909.3m USD
Long Term Debt = 3.65b USD (from longTermDebt, last quarter)
Short Term Debt = 35.0m USD (from shortTermDebt, last quarter)
Debt = 3.68b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.22b USD (calculated: Debt 3.68b - CCE 464.3m)
Enterprise Value = 14.5b USD (11.3b + Debt 3.68b - CCE 464.3m)
Interest Coverage Ratio = 2.81 (Ebit TTM 490.1m / Interest Expense TTM 174.6m)
EV/FCF = 33.06x (Enterprise Value 14.5b / FCF TTM 439.2m)
FCF Yield = 3.02% (FCF TTM 439.2m / Enterprise Value 14.5b)
FCF Margin = 6.62% (FCF TTM 439.2m / Revenue TTM 6.64b)
Net Margin = 5.08% (Net Income TTM 337.2m / Revenue TTM 6.64b)
Gross Margin = 31.59% ((Revenue TTM 6.64b - Cost of Revenue TTM 4.54b) / Revenue TTM)
Gross Margin QoQ = 31.49% (prev 31.73%)
Tobins Q-Ratio = 1.25 (Enterprise Value 14.5b / Total Assets 11.6b)
Interest Expense / Debt = 4.74% (Interest Expense 174.6m / Debt 3.68b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 387.2m (EBIT 490.1m * (1 - 21.00%))
Current Ratio = 1.89 (Total Current Assets 2.59b / Total Current Liabilities 1.37b)
Debt / Equity = 0.63 (Debt 3.68b / totalStockholderEquity, last quarter 5.84b)
Debt / EBITDA = 3.54 (Net Debt 3.22b / EBITDA 909.3m)
Debt / FCF = 7.33 (Net Debt 3.22b / FCF TTM 439.2m)
Total Stockholder Equity = 5.65b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.89% (Net Income 337.2m / Total Assets 11.6b)
RoE = 5.96% (Net Income TTM 337.2m / Total Stockholder Equity 5.65b)
RoCE = 5.27% (EBIT 490.1m / Capital Employed (Equity 5.65b + L.T.Debt 3.65b))
RoIC = 3.89% (NOPAT 387.2m / Invested Capital 9.96b)
WACC = 5.75% (E(11.3b)/V(15.0b) * Re(6.40%) + D(3.68b)/V(15.0b) * Rd(4.74%) * (1-Tc(0.21)))
Discount Rate = 6.40% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -79.24 | Cagr: -0.11%
[DCF] Terminal Value 73.10% ; FCFF base≈473.0m ; Y1≈414.8m ; Y5≈335.1m
[DCF] Fair Price = 3.19 (EV 5.38b - Net Debt 3.22b = Equity 2.16b / Shares 677.6m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -88.27 | EPS CAGR: -8.23% | SUE: 0.94 | # QB: 2
Revenue Correlation: -91.82 | Revenue CAGR: -2.12% | SUE: 1.49 | # QB: 4
EPS current Quarter (2027-03-31): EPS=0.19 | Chg30d=-4.32% | Revisions=+57% | Analysts=7
EPS current Year (2026-12-31): EPS=0.82 | Chg30d=+0.52% | Revisions=+25% | GrowthEPS=-9.2% | GrowthRev=+1.8%
EPS next Year (2027-12-31): EPS=0.89 | Chg30d=+0.62% | Revisions=+25% | GrowthEPS=+8.5% | GrowthRev=+2.9%
[Analyst] Revisions Ratio: +67% (up=6, down=0)